Kezar Life Sciences, Inc. — Director's Dealing 2019

Dec 20, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kezar Life Sciences, Inc. (KZR)
CIK: 0001645666
Period of Report: 2019-12-19

Reporting Person: Fowler John Franklin (Director, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-19	Common Stock	M	50000	$0.90	Acquired	346954	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-12-19	Employee Stock Option (Right to Buy)	$0.90	M	50000	Disposed	2025-09-09	Common Stock (50000)	Direct

Footnotes

F1: Fully vested.